ASX Announcements

Plans for Phase 3 trial in Rett syndrome
Neuren retains ex-North America, appoints investment bank
Appendix 4C - quarterly
Final Director's Interest Notice
Ceasing to be a substantial holder
2018 Year-end Business Update
Larry Glass to retire as a director and continue as CSO
Presentation at AusBiotech Invest and Partnering 2018
Appendix 4C - quarterly
Trofinetide ex-North America exclusive negotiation period